NOT KNOWN FACTUAL STATEMENTS ABOUT FIRSOCOSTAT

In conclusion, now available preclinical and clinical data support the development of GS-0976 as part of mixture therapy for NASH to minimize hepatic steatosis, lipotoxicity, and their downstream deleterious consequences.In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, triggered enhancements i